Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P15088 (
mast cell
)
14,925
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
phospholipase
(PL)A2 inhibitor p-bromophenacyl bromide (p-BPB), the antagonists of the platelet activating factor (PAF) 3-(4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)-(1,2,4)triazolo(4, 3-a)(1,4)diazepine-2-yl)-1-(4-morpholinyl)-1-propanone (a thieno-triazolo-diazepine, WEB 2086) and terpene-ginkgolide B and the antihistamine with PAF antagonistic qualities 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo[2,5]cyclo hep ta[1,2-b]thiophen-10-one (ketotifen) inhibit in the order p-BPB greater than terpene-ginkgolide B greater than ketotifen greater than WEB 2086 with decreasing activity the protamine sulphate activated histamine release from peritoneal rat mast cells (pRMC) in vitro. All compounds also inhibit the PAF induced aggregation of human platelets. The order of inhibition of the histamine release by these compounds does not agree with the order of their inhibitory activity on PAF induced aggregation of human platelets, indicating that the inhibition of the
mast cell
degranulation caused by PAF antagonists does not occur via PAF receptors. A generally membrane stabilizing quality of terpene-ginkgolide B and WEB 2086 may be ruled out as the cause of degranulation inhibition because none of the compounds suppresses the cytotoxic, triton X-100 induced release of histamine from pRMC. The mechanism of
mast cell
degranulation inhibition by PAF antagonists is unclear. An inhibition of PLA2 and/or inhibition of the Ca(2+)-activation are suggested.
...
PMID:Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro. 137 25
A cloned murine
mast cell
MC9 expresses
phospholipase
and lipoxygenase activity when stimulated with IgE and hapten. Addition of DNP-BSA to sensitized MC9 cells causes release of 58% of the cell histamine and 127 pmoles LTC4/10(6) cells. Prelabelling studies with [1-14C]-arachidonic acid showed that LTC4 production was proceeded by the release of arachidonic acid from membrane phospholipids. Approximately 8.7% of the cell arachidonic acid was released and half of this was converted to LTC4. The remaining radioactivity was converted to diHETES including LTB4 (15%), 5-HETE (10%), free arachidonic acid (10%), reesterified 5-HETE and arachidonic acid (8%) and prostaglandins (7%). This stimulation was dependent on hapten (DNP-BSA) and extracellular Ca++. Under identical conditions the calcium ionophore A23187 stimulated the release of 10.3% of the total cell arachidonic acid, and 51% of this was metabolized to LTC4. In addition the ionophore stimulated the release of 61% of the total cellular histamine.
...
PMID:Antigenic stimulated release of arachidonic acid, lipoxygenase activity and histamine release in a cloned murine mast cell MC9. 257 93
Insight into the pathogenesis of human allergic and inflammatory disorders has been obtained through a combination of in vitro and in vivo studies. These investigations have demonstrated that human basophils and mast cells release mediators after nonimmunologic as well as immunologic activation in vitro and in vivo: nonimmunologic triggers include changes in osmolarity. Although these cells share many properties, including the presence of high-affinity receptors for IgE on their cell surface, the presence of histamine in granules, the ability to generate and release large quantities of leukotriene C4 (LTC4) after activation, and the ability of several pharmacologic agents including
phospholipase
inhibitors, acetylene analogues of arachidonic acid (ETYA, ETI), methylxanthines, prostaglandin E2 (PGE2) beta-agonists, and cyclic AMP to inhibit mediator release, they also display notable differences. Human lung mast cells generate and release large quantities of prostaglandin D2 (PGD2) after activation; basophils generate no known cyclooxygenase product. Indomethacin, arachidonic acid, and 5-hydroperoxyeicosatetraenoic acid (5-HPETE) all enhance histamine and LTC4 release from human basophils; no effect is seen with human lung mast cells. Overnight incubation of basophils with glucocorticoids produces a marked inhibition of mediator release; this treatment does not affect the release of
mast cell
mediators. These in vitro observations are consistent with our in vivo observations and our hypotheses concerning the importance of these cells in allergic disease.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:The pharmacologic control of mediator release from human basophils and mast cells. 349 82
The venom of Apis mellifera was processed by gel permeation chromatography on Sephadex G-50 and by reversed-phase HPLC. The initial gel permeation step was carried out in the presence of phosphate ions (0.5 M). Ion pair reagents were required to resolve the strongly basic peptides, secapin,
mast cell
degranulating (MCD-) peptide and apamin, by reversed-phase (RP) HPLC. Using this relatively simple procedure it is possible to isolate these peptides essentially free of melittin (less than 1 in 10(7)) and
phospholipase
(less than 1 in 10(5] in high yield. The CD spectrum and secondary structure analysis are reported for MCD-peptide and on this basis a solution structure is proposed for this toxin.
...
PMID:Isolation and structure analysis of bee venom mast cell degranulating peptide. 381 6
Purified human lung mast cells released histamine, leukotrienes, prostaglandin (PG) D2, thromboxane B2 (TxB2), and PGF2 alpha in response to anti-IgE stimulation. Incubation of the cells for 24 h with 10(-6) M dexamethasone, a treatment that inhibits mediator release from human basophils, had no effect on the release of these mediators from mast cells. Dexamethasone treatment of human lung fragments led to little or no inhibition of anti-IgE-induced release of the
mast cell
-derived mediator, histamine, but produced a significant inhibition of the release of PGE2, PGF2 alpha, and 6-keto-PGF1 alpha. As was the case with purified mast cells, the steroid did not inhibit the release of PGD2 or TxB2 from human lung fragments. Comparison of the quantities of PGD2 and TxB2 produced by purified cells and human lung fragments reveals that the mast cells produce quantities of these metabolites sufficient to account for the entire amount produced by challenged lung fragments. Dexamethasone inhibited spontaneous release from lung fragments of all cyclooxygenase products measured. These results suggest that the human lung parenchymal
mast cell
phospholipase
is not inhibited by dexamethasone, whereas other
phospholipase
(s) in the lung are inhibited by the steroid. These results may be useful in explaining the resistance of acute allergic reactions, including anaphylaxis, to steroids, despite the potent antiinflammatory activity of steroids on subacute and chronic inflammation, such as in bronchial asthma, which may be initiated by IgE-dependent mechanisms.
...
PMID:Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. 613 55
Hydrocortisone and prednisolone inhibited the histamine release from isolated rat mast cells induced by antigen, the ionophore A23187, and compound 48/80 in the absence and in the presence of calcium. Hydrocortisone reduced the response to the different releasing agents by 50% in the concentration range 2-6 X 10(-4) M, whereas prednisolone was about 1.5 times more potent. The inhibitory effect of hydrocortisone had a rapid onset of action and maximal inhibition was observed after preincubation for 20 minutes. The effect of hydrocortisone was reversed by including 2 mM glucose in the medium. The reversal was only partial with antigen and the ionophore A23187, indicating a greater energy requirement of these releasing agents compared with compound 48/80. The inhibition of the histamine release was accompanied by a concentration-related inhibition of the 45Ca uptake, except with the ionophore. The inhibition of the 45Ca uptake was also reversed by glucose, but differences were noted concerning the influence of preincubation time. The observations are explained by an association of 45Ca to cellular material, e.g. granules, secondary to the release process. The effects of hydrocortisone and prednisolone were qualitatively identical and were not observed with estriol. The glucocorticoid inhibition of histamine release does not seem to be caused by effects on
phospholipase
activity or cyclic AMP metabolism. The present observations are fully consistent with an impaired mitochondrial function as the mechanism for the
mast cell
effects of the glucocorticoids.
...
PMID:Influence of glucocorticoids on histamine release and 45calcium uptake by isolated rat mast cells. 619 55
Two peptides rich in hydrophobic amino acids have been isolated from venom sacs of the European hornet, Vespa crabro. One peptide (P-2) is structurally and functionally related to the tetradecapeptide mastoparan and has been named mastoparan C. Leu-Asn-Leu-Lys-Ala-Leu-Leu-Ala-Val-Ala-Lys-Lys-Ile-LeuNH2. The other (P-1) is a tridecapeptide with a new sequence: Phe-Leu-Pro-Leu-Ile-Leu-Arg-Lys-Ile-Val-Thr-Ala-LeuNH2 which we have named crabrolin. The peptide releases histamine from rat peritoneal mast cells with a threshold of approximately 2.5 micrograms/ml (congruent to 8 microM). Crabrolin also facilitates the action of purified phospholipase A2 from different sources, but it is not quite as active as mastoparan. It is clearly less active than mastoparan in lysing erythrocytes, and it does not release amylase from dispersed guinea pig pancreatic acini. Given its unique sequence, the principal effect of crabrolin may be neither
mast cell
degranulation nor
phospholipase
facilitation, but a yet undiscovered action.
...
PMID:Isolation and characterization of two new peptides, mastoparan C and crabrolin, from the venom of the European hornet, Vespa crabro. 620 53
Highly purified porcine phospholipase A2 induced noncytotoxic rat cell degranulation, as indicated by release of histamine without release of the cytoplasmic marker lactate dehydrogenase. Ultrastructural studies using transmission, scanning, and freeze fracture electron microscopic techniques indicated that phospholipase A2-induced degranulation was comparable to that caused by other
mast cell
secretagogues. Secretory changes noted were fusion of perigranular and plasma membranes, formation of vacuoles containing less electron-dense granules, and exocytosis of the altered granules through pores in the plasma membrane, without alteration in other intracellular organelles. The earliest consistent feature of the exocytotic process (within 1 minute) was the formation of plasma membrane bulges overlying cytoplasmic granules, with depletion of intramembranous particles from the bulges and a reduction in surface microridges. Phospholipase A2-induced
mast cell
degranulation was blocked by the phospholipase inhibitor 4-bromophenacyl bromide and by eicosa-5,8,11,14-tetraynoic acid (ETYA) but not by indomethacin. Since ETYA inhibits both the cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism and indomethacin only the cyclooxygenase pathway, these findings are compatible with the mediation of phospholipase A2-induced
mast cell
degranulation by a lipoxygenase product of the released arachidonic acid ETYA, however, may inhibit
phospholipase
activity directly and thus affect degranulation by phospholipase A2 in this way. These studies indicate that phospholipase A2 can induce
mast cell
degranulation and provides evidence that is compatible with, but not proof of, mediation of this process by a lipoxygenase product of arachidonic acid metabolism.
...
PMID:Phospholipase A2-induced rat mast cell secretion. Role of arachidonic acid metabolites. 681 79
Inflammatory cytokines such as interleukin-1 (IL-1) have been implicated as paracrine mediators of decidual prostaglandin (PG) production during preterm labor. The aim of the present in vitro study was to investigate a similar potential role for the inflammatory autacoid histamine. Histamine action on human primary decidual cell cultures was monitored by measuring both PGF2 alpha production and PG precursor release. Histamine release from decidual cell suspensions was measured in response to a variety of putative
mast cell
secretagogues. Histamine stimulated a dose-dependent increase in PGF2 alpha production and [14C]arachidonate release from prelabeled decidual cells, with ED50 values around 1 and 2 mumol/L, respectively. Pretreatment of cells with IL-1 beta enhanced maximal PGF2 alpha production in response to histamine by approximately 4-fold. Mepyramine, an H1 receptor antagonist, completely blocked this PGF2 alpha response. The mean histamine content of unpurified decidual cells was approximately 81 pmol/10(6) cells. Upon challenge with antihuman immunoglobulin E, these cells exhibited a dose-dependent release of histamine. Basal release from decidual cell suspensions and release in response to antiimmunoglobulin E (1:400) or A23187 (1 mumol/L) were 7.6 +/- 2.7%, 25.5 +/- 0.9%, and 63.5 +/- 5.6% of the total histamine content, respectively. No significant changes in histamine secretion were seen in response to compound 48/80, substance-P, phorbol ester, or bacterial endotoxin. These in vitro findings support a potential role for histamine as a local regulator of
phospholipase
-A2 and PGF2 alpha production in human term decidua. The interaction of this autacoid with other inflammatory mediators, such as IL-1, could play a role in the control of PG production during preterm labor.
...
PMID:Decidual histamine release and amplification of prostaglandin F2 alpha production by histamine in interleukin-1 beta-primed decidual cells: potential interactive role for inflammatory mediators in uterine function at term. 753 17
Alcohol-induced hypersecretion probably contributes to chronic alcoholic pancreatitis. Feeding of raw soybean flour or soybean trypsin inhibitor also stimulates protein secretion of the pancreas. Therefore, we tested whether or not the pancreatic damage is increased by additional feeding of raw soybean flour in rats fed 20% ethanol. After 11 months, we classified the morphological lesions of the pancreas into seven stages of severity calculated by means of a discriminating procedure. In order to characterize the secretory capacity of the pancreas, we measured the outputs of lipase,
phospholipase
, A, alpha-amylase,
carboxypeptidase A
, chymotrypsin, and bicarbonate. Compared with the alcohol-fed animals, the rats fed with alcohol and soya exhibited a lower average degree of morphological damage in the pancreas. Hypertrophy and hyperplasia of the parenchyma and accumulation of secretory products within the acinar cells were main features. On the other hand, some separate regions of the pancreas showed intraductal secretion precipitates as well as plugs, which were sometimes associated with atrophy of acinar cells. Feeding with soybean diet grossly reduced the alcohol-induced enzyme hypersecretion. In the early phase of alcohol-induced pancreatic damage, long-term soybean flour diet thus reduces morphological lesions and hypersecretion of the rat pancreas, whereas protein synthesis in the acinar cells appears increased. However, the precipitation of secretory products on ductal epithelium, the increased formation of plugs, and the more frequent acinar atrophies suggest the development of significant tissue injuries.
...
PMID:[Modification of alcohol-induced pancreatic damage in rats by soybean diet]. 816 30
1
2
3
4
5
6
7
8
Next >>